FindTrial
Sign In

Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00370539
Enrollment
Unknown
Registered
2006-08-31
Start date
2006-09-30
Completion date
2006-11-30
Last updated
2006-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Age-Related Macular Degeneration

Keywords

Photodynamic therapy,, Bevacizumab,, Triamcinolone,, Age-related macular degeneration,, Choroidal neovascular membrane

Brief summary

To compare the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal bevacizumab versus combination of photodynamic therapy , intravitreal bevacizumab and intravitreal triamcinolone for neovascular AMD.

Interventions

DRUGverteporfin, bevacizumab, triamcinolone acetonide

Sponsors

Shahid Beheshti University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion criteria

* History of glaucoma or ocular hypertension * Disciform scar

Design outcomes

Primary

MeasureTime frame
Visual acuity—

Secondary

MeasureTime frame
Central macular thickness—
Leakage in fluorescein angiography—
Intraocular pressure—
Anterior chamber reaction—

Countries

Iran

Contacts

Primary ContactHamid Ahmadieh, MD
hahmadieh@hotmail.com+98 21 22585952

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026